NANJING, China, Oct. 15,
2013 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere"
or the "Company") (NYSE: SCR), a leading pharmaceutical company
specializing in the development, manufacturing, and marketing of
branded and proprietary pharmaceuticals in China, today announced the appointment of
Dr. Zang Jingwu as Chief Scientific Officer of the Company,
effective October 8, 2013.
Dr. Zang received his medical degree from Shanghai JiaoTong
University School of Medicine. He earned a PhD from the University
of Brussels and was a
post-doctoral fellow at Harvard Medical
School. Dr. Zang later joined the faculty of Baylor College of Medicine as a professor of
Neurology and holds a medical license in the State of Texas in US. In his career in
China, Dr. Zang was the founding
director of the Institute of Health Sciences and Institute Pasteur
Shanghai of the Chinese Academy of Sciences. In 2007, Dr. Zang
joined GSK as Senior VP and head of GSK's R&D Centre in
China; and in 2012, he held one
more position as the global head of Neurosciences Therapy Area in
GSK.
Mr. Hongquan Liu, the Chief
Executive Officer of Simcere, said, "We are extremely pleased that
Jingwu will be joining the Simcere management team to lead our
R&D efforts. With his rich industry experience and solid
knowledge of new drug development, we are confident that Jingwu
will be an important contributor to Simcere as we continue to
broaden our pipeline of innovative medicines."
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE:
SCR) is a leading pharmaceutical company specializing in the
development, manufacturing, and marketing of branded and
proprietary pharmaceuticals in China. Simcere concentrates its research and
development efforts on the treatment of diseases with high
incidence and/or mortality rates and for which there is a clear
demand for more effective pharmacotherapy such as cancer, strokes,
cardiovascular disease, infectious diseases and pain. For more
information about Simcere Pharmaceutical Group, please visit
www.simcere.com.
Investor and Media Contacts:
Email: ir@simcere.com
In
Nanjing:
Vivien
Liang
Simcere
Pharmaceutical Group
Tel:
86-25-8556-6666*8857
|
In the United
States:
Cindy
Zheng
Brunswick Group
LLC
Tel:
1-212-333-3810
|
|
|
In
Beijing:
Yue Yu
Brunswick
Group
Tel:
86-10-5960-8600
|
|
SOURCE Simcere Pharmaceutical Group